Key result
Anlotinib treatment in a 49-year-old male with advanced squamous cell carcinoma induced acute myocardial infarction after 14 months of therapy.
Why the study?
Anlotinib has cardiovascular toxicity, but the risk of developing acute myocardial infarction had not been assessed by previous clinical trials or research.
Does anlotinib treatment cause acute myocardial infarction in patients with advanced non-small cell lung cancer?
Case Report (n=1)
Does anlotinib treatment cause acute myocardial infarction in patients with advanced non-small cell lung cancer?
This is the first reported case of anlotinib-induced acute myocardial infarction, highlighting the need for cardiovascular monitoring in patients receiving this anti-angiogenic therapy.
May warrant CV monitoring with anlotinib; first case leaves open causality and incidence in NSCLC.
Anlotinib hydrochloride is a multi-target tyrosine kinase inhibitor, which has been recently approved for the treatment of advanced non-small cell lung cancer in China. One of its mechanisms of action is the inhibition of angiogenesis and it is similar to other anti-angiogenesis drugs, as it has cardiovascular toxicity, which may damage vascular endothelial cells and result in hypertension and hyperlipidemia. All of the aforementioned factors are considered risk factors for coronary heart disease; however, the risk of developing acute myocardial infarction (AMI) has not been assessed by any previous clinical trials and subsequent research. The present case study, to the best of our knowledge, was the first to report on a patient who developed hypertension, hyperlipidemia and angina pectoris, and eventually experienced AMI, following treatment with anlotinib. This indicates that patients receiving anlotinib may require further observation and monitoring during use.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2020) conducted a case report in Advanced squamous cell carcinoma (n=1). Anlotinib was evaluated on Acute myocardial infarction. Anlotinib treatment in a 49-year-old male with advanced squamous cell carcinoma induced acute myocardial infarction after 14 months of therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: